Journal of Cancer Research and Therapeutics

Scope & Guideline

Uniting researchers to combat cancer effectively.

Introduction

Delve into the academic richness of Journal of Cancer Research and Therapeutics with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN0973-1482
PublisherWOLTERS KLUWER MEDKNOW PUBLICATIONS
Support Open AccessNo
CountryIndia
TypeJournal
Convergefrom 2005 to 2024
AbbreviationJ CANCER RES THER / J. Canc. Res. Ther.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressWOLTERS KLUWER INDIA PVT LTD, A-202, 2ND FLR, QUBE, C T S NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra 400059, INDIA

Aims and Scopes

The Journal of Cancer Research and Therapeutics focuses on the latest advancements in cancer research, therapeutic strategies, and clinical practices. It serves as a platform for disseminating innovative findings that enhance understanding and treatment of cancer, while also addressing the multifaceted challenges faced by oncology professionals.
  1. Clinical Trials and Therapeutics:
    The journal emphasizes the reporting of clinical trials and therapeutic interventions across various cancer types, providing insights into efficacy, safety, and patient outcomes.
  2. Molecular and Cellular Biology of Cancer:
    Research on the molecular mechanisms underlying cancer development and progression is a core focus, including studies on genetic mutations, signaling pathways, and tumor microenvironment interactions.
  3. Radiotherapy and Interventional Techniques:
    The journal includes research on advancements in radiotherapy techniques, such as intensity-modulated radiation therapy (IMRT) and brachytherapy, as well as interventional approaches like ablation and chemoembolization.
  4. Cancer Epidemiology and Prevention:
    Epidemiological studies exploring risk factors, prevention strategies, and population-based cancer trends are highlighted to inform public health initiatives.
  5. Innovative Diagnostic Approaches:
    The journal covers novel diagnostic techniques, including imaging advancements and biomarker discovery, that aid in the early detection and accurate characterization of tumors.
  6. Patient Care and Quality of Life:
    Research addressing the psychosocial aspects of cancer care, including quality of life assessments and supportive care strategies, is integral to the journal's scope.
The Journal of Cancer Research and Therapeutics has witnessed emerging themes that reflect the dynamic nature of cancer research, driven by technological advances and changing patient needs. These trends highlight the journal's commitment to addressing contemporary challenges in oncology.
  1. Immunotherapy and Personalized Medicine:
    There is a growing emphasis on research related to immunotherapy approaches and personalized treatment plans tailored to individual genetic profiles, reflecting a paradigm shift in cancer treatment.
  2. Molecular Targeted Therapy:
    Studies focusing on targeted therapies that inhibit specific molecular pathways are increasingly prominent, showcasing advancements in drug development and efficacy.
  3. Artificial Intelligence and Machine Learning in Oncology:
    The integration of AI and machine learning techniques in cancer diagnosis, treatment planning, and outcome prediction is a rapidly emerging area, enhancing the precision of oncology practices.
  4. Cancer Genomics and Biomarkers:
    Research into cancer genomics, including the identification of biomarkers for early detection and therapeutic response, is on the rise, facilitating advancements in precision oncology.
  5. Quality of Life and Patient-Centered Care:
    There is an increasing focus on research that evaluates the quality of life for cancer patients, addressing the psychosocial aspects of treatment and survivorship.
  6. Novel Therapeutic Delivery Systems:
    Emerging studies on innovative drug delivery systems, such as nanoparticles and nanocarriers, are gaining traction as they promise to enhance the efficacy of cancer therapies.

Declining or Waning

While the Journal of Cancer Research and Therapeutics continues to evolve, certain research areas have experienced a decline in focus. This shift may reflect changes in scientific interest, advancements in technology, or the emergence of more pressing issues in cancer research.
  1. Traditional Chemotherapy Studies:
    Research specifically focused on traditional chemotherapy regimens has waned, possibly due to the increasing interest in targeted therapies and immunotherapies that offer improved outcomes.
  2. Single-Agent Studies:
    There has been a noticeable decrease in studies evaluating the efficacy of single-agent therapies, as the trend shifts towards combination therapies that leverage synergistic effects.
  3. Basic Science Research on Common Cancer Types:
    Basic research on well-characterized cancer types (e.g., breast, lung) has reduced, as researchers increasingly explore rarer malignancies or investigate complex interactions in tumor biology.
  4. Conventional Imaging Techniques:
    The reliance on conventional imaging modalities for cancer diagnosis is declining, as advanced techniques such as molecular imaging and radiomics gain prominence.
  5. Palliative Care Research:
    While still important, the volume of research specifically focused on palliative care strategies has decreased, possibly overshadowed by curative treatment advancements.

Similar Journals

Cancer Reports

Elevating cancer knowledge to improve patient outcomes.
Publisher: WILEYISSN: Frequency: 12 issues/year

Cancer Reports, published by WILEY, is an esteemed open-access journal dedicated to the field of oncology and cancer research. With a focus on disseminating impactful research findings since its transition to fully open access in 2021, Cancer Reports aims to facilitate knowledge sharing among researchers, clinicians, and healthcare professionals globally. The journal is positioned within the Q3 quartile for both Cancer Research and Oncology categories as of 2023, reflecting its commitment to quality and relevance in a competitive publishing landscape. With an ISSN of N/A and an E-ISSN of 2573-8348, the journal showcases studies across diverse aspects of cancer biology, treatment modalities, and patient care strategies. Located in the United Kingdom at 111 River St, Hoboken 07030-5774, NJ, Cancer Reports strives to contribute to the advancement of cancer research and improve health outcomes for patients worldwide, making it a pivotal platform for scholars and practitioners in the oncology community.

Nature Reviews Clinical Oncology

Pioneering Insights for Tomorrow's Treatments
Publisher: NATURE PORTFOLIOISSN: 1759-4774Frequency: 12 issues/year

Nature Reviews Clinical Oncology is a premier journal dedicated to the comprehensive exploration and critical evaluation of current advancements in the field of clinical oncology. Published by the esteemed NATURE PORTFOLIO in the United Kingdom, this influential journal boasts an impressive impact factor that reflects its significant role in shaping oncology research. As a Q1 ranked journal in Scopus, it occupies a notable position within the top tier of oncology publications, placing it in the 99th percentile among its peers. With a history of convergence from 2009 to 2024, it presents high-quality content through an open-access model, ensuring accessibility to vital research findings. Researchers, professionals, and students alike will find Nature Reviews Clinical Oncology an invaluable resource for staying abreast of the latest trends, biologic insights, and therapeutic innovations that drive the future of cancer treatment.

Translational Cancer Research

Catalyzing progress in oncology and imaging sciences.
Publisher: AME PUBLISHING COMPANYISSN: 2218-676XFrequency: 12 issues/year

Translational Cancer Research, published by AME Publishing Company in Hong Kong, is a pivotal journal aimed at fostering the advancement of oncology-related knowledge through the dissemination of high-quality research findings. With its ISSN 2218-676X and E-ISSN 2219-6803, this journal serves as a vital resource for researchers, professionals, and students in the fields of Cancer Research, Oncology, and Radiology, Nuclear Medicine, and Imaging. Established in 2012, the journal covers the latest breakthroughs and cross-disciplinary approaches that drive innovation in cancer treatment and diagnostics. Although currently classified in the Q4 Quartile for Cancer Research and Q3 for both Oncology and Radiology, Translational Cancer Research continuously works toward improving its academic influence and impact, evidenced by its ongoing research contributions. The journal emphasizes open access, making crucial research available to a global audience. We invite scholars and industry professionals to engage with the latest findings and discussions within these critical areas of medical science.

INTERNATIONAL JOURNAL OF CANCER

Shaping the future of oncology through rigorous research.
Publisher: WILEYISSN: 0020-7136Frequency: 24 issues/year

INTERNATIONAL JOURNAL OF CANCER, published by Wiley, stands as a premier platform for the dissemination of cutting-edge research in the fields of cancer research and oncology. With an impressive impact factor reflecting its rigorous peer-review process and significant contribution to the scientific community, this journal is categorized in Q1 for both Cancer Research and Oncology as of 2023. It boasts notable rankings, being placed 38th among 404 journals in Medicine - Oncology and 32nd among 230 in Biochemistry, Genetics, and Molecular Biology - Cancer Research, positioning it within the 90th and 86th percentiles, respectively. Since its inception in 1966 and continuing to 2024, the journal has played a pivotal role in advancing our understanding of cancer biology, treatment modalities, and innovative therapeutic approaches. While it operates under a subscription model, the journal is committed to making valuable research accessible to a broader scientific audience. Researchers, professionals, and students alike will find the INTERNATIONAL JOURNAL OF CANCER an essential resource for staying abreast of the latest advancements in cancer science.

CANCER BIOLOGY & THERAPY

Transforming cancer treatment through cutting-edge research.
Publisher: TAYLOR & FRANCIS INCISSN: 1538-4047Frequency: 12 issues/year

CANCER BIOLOGY & THERAPY is a premier open-access journal published by Taylor & Francis Inc, dedicated to advancing the field of cancer research and treatment. Since its inception in 2002, the journal has evolved to provide a platform for innovative research and groundbreaking findings, addressing critical aspects of cancer biology, pharmacology, and molecular medicine. With an impressive impact factor and recognition as a Q2 journal in vital categories such as Cancer Research, Oncology, and Pharmacology, it holds significant standing in Scopus rankings, reflecting its influence and commitment to disseminating high-quality research. Offering researchers, professionals, and students a wealth of knowledge, CANCER BIOLOGY & THERAPY stands at the forefront of the fight against cancer, presenting the latest developments and therapeutic strategies vital for improving patient outcomes. Accessible to all since 2022, this journal is a must-read for anyone involved in the multifaceted arena of cancer research and treatment.

CANCER INVESTIGATION

Pioneering insights in oncology for a healthier tomorrow.
Publisher: TAYLOR & FRANCIS INCISSN: 0735-7907Frequency: 10 issues/year

CANCER INVESTIGATION is a distinguished peer-reviewed journal published by Taylor & Francis Inc, dedicated to the advancing field of cancer research and oncology. With an ISSN of 0735-7907 and E-ISSN of 1532-4192, this journal has been a pivotal resource for professionals and researchers since its inception in 1983, continually contributing to the evolving landscape of cancer investigation until its convergence in 2024. CANCER INVESTIGATION boasts noteworthy rankings in 2023, including Q3 in Cancer Research and Q2 in Medicine (miscellaneous), highlighting its relevance and impact in these critical areas. The journal's commitment to disseminating innovative research and comprehensive reviews makes it an essential platform for those engaged in cancer studies and related disciplines. While currently not available as an open-access publication, CANCER INVESTIGATION remains an invaluable tool for understanding the complexities of cancer, offering insights that drive scientific advancements and improve patient outcomes.

PROSTATE

Fostering collaboration for breakthroughs in urology and oncology.
Publisher: WILEYISSN: 0270-4137Frequency: 16 issues/year

PROSTATE is a premier, peer-reviewed journal published by Wiley, focusing on the critical fields of urology and oncology. With an established history since 1980 and a projected convergence through 2024, this influential journal serves as a vital resource for researchers, clinicians, and students alike. It holds a prestigious position in the academic landscape, classified in the Q1 category for Urology and Q2 in Oncology as of 2023, demonstrating its significant contribution to these disciplines. With a Scopus rank of #23 in Urology and #169 in Oncology, PROSTATE is pivotal for advancing knowledge and fostering innovation in prostate research, treatment, and overall male health. The journal aims to publish high-quality original articles, reviews, and clinical studies that address the complexities of prostate-related conditions, ultimately seeking to improve patient outcomes and propagate best practices in the medical community.

MOLECULAR CANCER RESEARCH

Exploring Breakthroughs in Cancer Biology
Publisher: AMER ASSOC CANCER RESEARCHISSN: 1541-7786Frequency: 12 issues/year

MOLECULAR CANCER RESEARCH, published by the American Association for Cancer Research, stands as a pivotal journal in the fields of cancer research, molecular biology, and oncology. With an impressive impact factor and recognized as a Q1 journal in its respective categories for 2023, it serves as an essential resource for researchers, professionals, and students aimed at advancing our understanding of cancer mechanisms and therapies. The journal, identified by the ISSN 1541-7786 and E-ISSN 1557-3125, provides a platform for cutting-edge research and clinical applications, emphasizing innovation and collaboration within the scientific community. With its focus on high-quality, peer-reviewed articles, MOLECULAR CANCER RESEARCH is vital for anyone looking to stay abreast of significant advancements in cancer biology and treatment strategies. For more details and to access the journal's content, please visit the publisher's link.

Oncologie

Advancing cancer research for a healthier tomorrow.
Publisher: WALTER DE GRUYTER GMBHISSN: 1292-3818Frequency: 6 issues/year

Oncologie is a distinguished academic journal published by WALTER DE GRUYTER GMBH, focusing on the dynamic and vital field of oncology. Established in 1999 and continuously published until 2024, this journal provides a platform for high-quality research and advancements in cancer treatment, prevention, and diagnosis. With an ISSN of 1292-3818 and an E-ISSN of 1765-2839, it is indexed in various databases, contributing to its growing visibility. Although categorized in the Q3 quartile for oncology research as of 2023, Oncologie offers essential insights and fosters scholarly dialogue among researchers, professionals, and students interested in oncology. Its unique contributions aim to bridge the gap between theoretical frameworks and clinical applications, making it a valuable resource for those seeking to advance their knowledge and expertise in cancer research.

CURRENT CANCER DRUG TARGETS

Connecting knowledge and innovation in cancer drug development.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1568-0096Frequency: 11 issues/year

CURRENT CANCER DRUG TARGETS is a prominent academic journal published by Bentham Science Publishers Ltd, focusing on the critical intersection of cancer research and innovative drug development. Since its inception in 2001, this journal has offered a platform for the dissemination of cutting-edge research aimed at advancing targeted cancer therapies, contributing significantly to the fields of Cancer Research, Drug Discovery, Oncology, and Pharmacology. With a respectable impact factor and consistent ranking in its respective categories, including Q2 in Drug Discovery and Pharmacology, it positions itself as an invaluable resource for researchers, clinicians, and students alike. CURRENT CANCER DRUG TARGETS is dedicated to enhancing our understanding of novel therapeutic targets and methods, thereby fostering a collaborative environment for knowledge exchange in the ever-evolving landscape of cancer treatment.